Startup profile · funding coverage
GC Therapeutics funding, valuation and investors
Cell-therapy biotech using George Church–originated iPSC programming platform TFome.
Keep track of GC Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$65M · 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$65M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Cambridge, Massachusetts
Overview
GC Therapeutics (GCTx) develops off-the-shelf cell therapies using TFome, a proprietary iPSC programming platform originated from George Church's lab — aiming to manufacture consistent cell products at scale.
Why GC Therapeutics is interesting
GC Therapeutics targets scalable off-the-shelf cell therapies; a16z Bio + Health joined Pear VC in its $65M Series A launch round.
Product & use cases
GC Therapeutics (GCTx) uses TFome, an iPSC programming platform from George Church's lab, to manufacture off-the-shelf cell therapies at scale.
- Off-the-shelf regenerative cell products
- Consistent iPSC-derived therapies vs. autologous manufacturing
- Platform licensing for cell therapy developers
Key facts
- Series A (2024): $65M led by Cormorant Asset Management with a16z Bio + Health (/fund/andreessen-horowitz) and Pear VC (/fund/pear-vc) (BusinessWire)
- TFome platform originated from George Church's lab at Harvard; targets scalable off-the-shelf iPSC cell therapies
Funding history (newest first)
Series A
2024 $65M- Cormorant Asset Management (lead)
- Andreessen Horowitz (participant)
- Pear VC (participant)
Investors in our directory
Funds linked from GC Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: TFome platform originated in George Church's Harvard lab — targets manufacturing consistency that autologous cell therapy lacks.
Off-the-shelf cell therapy is a crowded thesis; GCTx bets TFome programming from Church lab IP delivers repeatable products. Clinical validation still ahead.
-
Fate Therapeutics direct
iPSC-derived cell therapies; GCTx differentiates on TFome programming.
-
Century Therapeutics direct
iPSC NK/T cell programs; overlapping off-the-shelf thesis.
-
Autologous CAR-T makers alternative
Patient-specific manufacturing; higher cost, harder scale.
Notable stories
- TFome platform originated from George Church's lab at Harvard (BusinessWire, 2024).
- Launched with $65M Series A to advance off-the-shelf iPSC cell therapies.
Industries
Related funding articles
Venture Capital Tracker pieces that cover GC Therapeutics's financing or category context.
FAQs about GC Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.